MD772Z - Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare - Google Patents
Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare Download PDFInfo
- Publication number
- MD772Z MD772Z MDS20130156A MDS20130156A MD772Z MD 772 Z MD772 Z MD 772Z MD S20130156 A MDS20130156 A MD S20130156A MD S20130156 A MDS20130156 A MD S20130156A MD 772 Z MD772 Z MD 772Z
- Authority
- MD
- Moldova
- Prior art keywords
- urinary bladder
- nanodiamonds
- concentration
- administered
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 208000006994 Precancerous Conditions Diseases 0.000 title claims abstract description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract description 5
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract description 4
- 239000002113 nanodiamond Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008169 grapeseed oil Substances 0.000 claims abstract description 6
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 210000003932 urinary bladder Anatomy 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 208000002741 leukoplakia Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 238000002574 cystoscopy Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 241001351283 Arta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011324 primary prophylaxis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000016525 transitional cell neoplasm Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130156A MD772Z (mo) | 2013-09-18 | 2013-09-18 | Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20130156A MD772Z (mo) | 2013-09-18 | 2013-09-18 | Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD772Y MD772Y (en) | 2014-05-31 |
| MD772Z true MD772Z (mo) | 2014-12-31 |
Family
ID=50882640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20130156A MD772Z (mo) | 2013-09-18 | 2013-09-18 | Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD772Z (mo) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100020849A1 (it) * | 2021-08-03 | 2023-02-03 | Moss Pharma S R L | Nuovo uso di olio ozonizzato |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2257219C1 (ru) * | 2004-07-16 | 2005-07-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ (ЦНИРРИ) | Способ лечения инвазивного рака мочевого пузыря |
| RU2257912C1 (ru) * | 2004-01-13 | 2005-08-10 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения рака мочевого пузыря |
| RU2390341C2 (ru) * | 2008-08-08 | 2010-05-27 | Олег Борисович Лоран | Способ консервативного лечения лейкоплакии (плоскоклеточной метаплазии) мочевого пузыря |
| MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
| RU2448745C2 (ru) * | 2010-05-31 | 2012-04-27 | Олег Феликсович Каган | Способ лечения поверхностного рака мочевого пузыря |
| RU2457846C2 (ru) * | 2010-07-05 | 2012-08-10 | Александр Анатольевич Зимичев | Способ лечения при раке мочевого пузыря |
-
2013
- 2013-09-18 MD MDS20130156A patent/MD772Z/mo not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2257912C1 (ru) * | 2004-01-13 | 2005-08-10 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения рака мочевого пузыря |
| RU2257219C1 (ru) * | 2004-07-16 | 2005-07-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ (ЦНИРРИ) | Способ лечения инвазивного рака мочевого пузыря |
| RU2390341C2 (ru) * | 2008-08-08 | 2010-05-27 | Олег Борисович Лоран | Способ консервативного лечения лейкоплакии (плоскоклеточной метаплазии) мочевого пузыря |
| MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
| RU2448745C2 (ru) * | 2010-05-31 | 2012-04-27 | Олег Феликсович Каган | Способ лечения поверхностного рака мочевого пузыря |
| RU2457846C2 (ru) * | 2010-07-05 | 2012-08-10 | Александр Анатольевич Зимичев | Способ лечения при раке мочевого пузыря |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100020849A1 (it) * | 2021-08-03 | 2023-02-03 | Moss Pharma S R L | Nuovo uso di olio ozonizzato |
Also Published As
| Publication number | Publication date |
|---|---|
| MD772Y (en) | 2014-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Early stage blood purification for paraquat poisoning: a multicenter retrospective study | |
| Neheman et al. | Hyperbaric oxygen therapy for radiation‐induced haemorrhagic cystitis | |
| Qiao et al. | Total flavone of abelmoschus manihot ameliorates TNBS-induced colonic fibrosis by regulating Th17/Treg balance and reducing extracellular matrix | |
| Qiu et al. | Wenzi Jiedu Recipe ameliorates colorectal cancer by remodeling the gut microbiota and tumor microenvironment | |
| MD772Z (mo) | Metodă de tratament al stărilor precanceroase şi al cancerului neinvaziv al vezicii urinare | |
| CN108653319A (zh) | 臭氧化油在妇科炎症疾病中的应用 | |
| WO2010004653A1 (ja) | ヘリコバクターピロリ菌の駆除剤並びに駆除方法 | |
| CN105380956B (zh) | 一种治疗白血病的含艾德拉尼的药物组合物及应用 | |
| RU2360712C1 (ru) | Способ лечения местно-распространенного неоперабельного рака прямой кишки | |
| EP1677811A1 (en) | Medicament on the basis of honey, preparation and use thereof | |
| Zhang et al. | Protective effect of nanoparticles from platycladi cacumen carbonisata on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-Induced colitis in rats | |
| CN116115591B (zh) | 厚朴酚单体化合物及其在防治肠道辐射损伤中的应用 | |
| Lunglmayr et al. | Bladder hyperthrmia in the treatment of vesical papillomatosis | |
| CN102416116B (zh) | 一种治疗声带小结的中药制剂 | |
| CN107041895A (zh) | 用以抑制肾癌细胞增生与改善肾功能的灵樟芝组合物 | |
| CN107048104A (zh) | 一种用于辅助治疗糖尿病的虾青素饮料 | |
| Iwamoto et al. | Upper hemibody infusion of cis-diamminedichloroplatinum (II) followed by systemic antidote, sodium thiosulfate, for lung metastasis in rats | |
| TWI549677B (zh) | Ｕｇｏｎｉｎ化合物於製備治療皮膚癌藥物之用途 | |
| RU2134589C1 (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени | |
| Zhang et al. | Nano-enabled repurposing of Benproperine phosphate enhances pancreatic Cancer chemotherapy through lethal autophagy arrest and immune activation | |
| JP2011503051A (ja) | 過酸化油及びコレステロールを含む医薬組成物並びに医療分野におけるこれらの使用 | |
| CN110051734A (zh) | 一种抗结肠炎相关性结肠癌的药物组合物及其应用 | |
| US20100260870A1 (en) | Method and preparations for treating infection-allergic diseases | |
| Seo et al. | A case of stomach cancer patient with peritoneum and colon metastasis treated with Taeumjowi-tang for abdominal pain and diarrhea | |
| WO2009138094A1 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MK4Y | Short term patent expired | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |